Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | FPR3 | P25089 | 3/20 | 0.42 |
| ▸ | FPR2 | P25090 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 4/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26930774 | 0.83 | TSHR (0.54) | TSHRALOX15ATMRORCJAK2 | |
| SCHEMBL26930067 | 0.81 | TSHR (0.53) | TSHRALOX15ATMRORCJAK2 | |
| SCHEMBL26930433 | 0.81 | TSHR (0.51) | TSHRALOX15ATMRORCJAK2 | |
| SCHEMBL12988312 | 0.81 | TSHR (0.53) | TSHRALOX15ATMRORCJAK2 | |
| SCHEMBL4629887 | 0.79 | TSHR (0.49) | TSHRALOX15ATMRORCJAK2 | |
| SCHEMBL16764525 | 0.75 | RORC (0.53) | TSHRALOX15ATMRORCJAK2 | |
| SCHEMBL1199600 | 0.75 | RORC (0.51) | TSHRALOX15ATMRORCJAK2 | |
| SCHEMBL2470131 | 0.75 | TSHR (0.64) | TSHRALOX15ATMMEN1KMT2A | |
| SCHEMBL1938618 | 0.75 | RORC (0.48) | TSHRALOX15ATMRORCJAK2 | |
| SCHEMBL3022366 | 0.75 | RORC (0.48) | TSHRALOX15ATMRORCJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-11-27 | — | — | US | disclosed |
| EP-4536657-A1 | LATS INHIBITORS AND USES THEREOF | The USA, as represented by The Secretary, Department of Health and Human Services (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023239727-A1 | LATS INHIBITORS AND USES THEREOF | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | LATS2, LATS1, AKT1S1 | TSHR 2427/4885ALOX15 1115/4885ATM 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.